A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment

Journal of Interferon and Cytokine Research

Volumn 31, Issue 6, 2011, Pages 481-483

  Bosch, Ronald J ^a   Pollard, Richard B ^b   Landay, Alan ^c   Aga, Evgenia ^a   Fox, Lawrence ^d   Mitsuyasu, Ronald ^e  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; INTERLEUKIN 2; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MIDDLE AGED; RNA, VIRAL; VIRUS REPLICATION; WITHHOLDING TREATMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79958227902     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2010.0119     Document Type: Article

References (10)

1. Abrams D, Lévy Y, Losso MH, and others. 2009. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 361: 1548-1559.
2. Barouch DH, Craiu A, Kuroda MJ, and others. 2000. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 97:4192-4197. (Pubitemid 30226109)
3. Bosch RJ, Pollard RB, Landay A, and others. 2010. Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG protocol A328). AIDS Res Ther 7:30.
4. Goujard C, Marcellin F, Hendel-Chavez H, and others. 2007. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: Impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 randomized study. AIDS Res Hum Retro-viruses 23:1105-1113. (Pubitemid 47571934)
5. Jacobson JM, Bucy RP, Spritzler J, and others. 2006. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: The results of AIDS Clinical Trials Group 5068. J Infect Dis 194:623-632. (Pubitemid 44297848)
6. Kilby JM, Bucy RP, Mildvan D, and others. 2006. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis 194:1672-1676. (Pubitemid 44901997)
7. Kuekrek H, Schlingmann T, Valdez H, and others. 2005. Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. AIDS 19:1967-1974. (Pubitemid 41669020)
8. Kutzler MA, Jacobson JM. 2008. Treatment interruption as a tool to measure changes in immunologic response to HIV-1. Curr Opin HIV AIDS 3:131-135. (Pubitemid 351322825)
9. Oxenius A, Price DA, Günthard HF, and others. 2002. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci 99:13747-13752. (Pubitemid 35215452)
10. Stellbrink HJ, van Lunzen J, Westby M, and others. 2002. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 16:1479-1487. (Pubitemid 34804212)